Healthy Returns Ahead: Investor Outlook for the Telemedicine Sector

The COVID-19 pandemic accelerated a trend that was already underway – the transition to virtual healthcare. Telehealth and telemedicine platforms that enable patient-doctor video visits surged in popularity with the rise of social distancing. This shift towards healthcare digitization appears poised to continue shaping the industry landscape long after the pandemic subsides.

Companies at the forefront of virtual care technology saw demand for their platforms skyrocket since early 2020. Now, with telehealth becoming entrenched in patient and provider norms, these virtual health firms are emerging as stocks to watch. Their continued growth could transform how healthcare is accessed and delivered.

Surging into the Mainstream

The coronavirus outbreak necessitated remote interactions, making virtual doctor appointments a necessity. Healthcare providers rapidly ramped up telehealth offerings to comply with public health mandates while ensuring patient access.

According to McKinsey, telehealth utilization soared from 11% of US consumers in 2019 to 46% in 2020. Virtual healthcare visits increased 38-fold from the pre-pandemic baseline.

This abrupt shift illuminated the viability of remote care. Patients and providers alike found telehealth appointments efficient and convenient compared to in-office visits. Virtual options grant easy access for patients while maximizing provider capacity.

Significant majorities of patients now prefer a telehealth option according to surveys. With Covid risks waning, medical practices face patient demand to maintain virtual visit capabilities. This bodes well for companies specializing in telemedicine software and infrastructure.

“Virtual care proved its worth during an extremely trying time for the healthcare system,” said Alan Warren, MD and Chief Medical Officer of Epic Health Services. “Now patients know its value. Providers have invested in it. There’s no going back.”

New Market Leader?

Hims & Hers Health (NYSE: HIMS) operates a telehealth platform focused on serving millennial and gen-Z demographics. Its model emphasizes accessible virtual care for conditions like skin, sexual health, mental health, and primary care.

Since pandemic onset, Hims & Hers has seen tremendous growth as young consumers flocked to its digital offerings. Quarterly revenues grew 74% year-over-year in Q3 2023. The company now boasts over a million subscribers and expanded its medical provider network 10-fold.

Hims & Hers shares surged over 15% this past week on the back of strong Q3 results that beat analyst estimates. The company increased its FY 2023 revenue guidance by $5 million.

As adoption of virtual care increases, platforms like Hims & Hers that cater to digital-native populations could see outsized gains. Younger demographics are leading the charge in embracing telehealth’s convenience and privacy.

“Hims & Hers is emerging as uniquely positioned to capture the virtual care market for younger users who prefer seeking healthcare from their smartphones,” said Morgan Stanley analyst Daniella Perry. She projects the company will top $500 million in sales by 2025.

The New Normal

While uncertainty always exists around new technologies, virtual healthcare appears poised for growing prominence even post-pandemic. Patients favor the enhanced access, efficiency, and safety it affords. Providers can boost capacity and revenue with integrated telemedicine capabilities.

Regulatory changes also signal momentum. Recently proposed congressional legislation aims to permanently remove geographic restrictions on telehealth while increasing reimbursements to incentivize adoption. If passed, such measures would further propel widespread virtual care.

Meanwhile, more providers are investing in platforms to offer hybrid models blending physical and digital visits. Partnerships between health systems and technology vendors are becoming commonplace.

“Virtual healthcare is becoming standard,” said John Smith, Chief Medical Officer at MedCity Health. “We’ve implemented secure video visit capabilities across all our primary care clinics. Patients love the flexibility of on-demand telehealth for many common conditions and follow-ups.”

For innovative companies enabling this care transformation, analysts see blue sky ahead. As telehealth becomes entrenched in care delivery norms, firms providing user-friendly, scalable platforms could capture enormous value. The next time you need to see a doctor, the visit may very likely take place online.

Science 37 to be Acquired by eMed in Deal to Expand Virtual Clinical Trials

Clinical research company Science 37 announced Monday that it has entered into a definitive agreement to be acquired by telehealth provider eMed in a deal valued at approximately $38 million. Under the agreement, eMed will commence a tender offer to purchase all outstanding shares of Science 37 stock for $5.75 per share in cash, representing a 21.3% premium over Science 37’s share price last week.

The deal will allow eMed to leverage Science 37’s remote clinical trial capabilities and proprietary Metasite technology platform to expand patient access and accelerate enrollment for clinical studies. Science 37’s decentralized clinical trial model enables patients to participate from home via telehealth, rather than having to travel to physical trial sites.

This acquisition comes at a pivotal time, as the biotech industry embraces virtual and hybrid trial designs in the wake of the COVID-19 pandemic. Science 37 was an early pioneer in decentralized trials, giving the company a first-mover advantage. According to Science 37 CEO David Coman, “eMed provides the greatest value to our stockholders, customers, patients, and employees. Stockholders will receive a premium, trial sponsors will gain greater access to patients, faster enrollment, and confidence in the Company’s capital position.”

For eMed, the deal significantly expands its digital healthcare footprint, adding Science 37’s network of telehealth investigators, coordinators, and software platform to its existing suite of at-home diagnostics and virtual care services. eMed was an early mover as well, having developed the first at-home COVID-19 test kit in 2020. Since then, the company has expanded into at-home testing and treatment for flu, UTIs, and other conditions.

The combined resources of both companies will provide end-to-end support for decentralized clinical trials, from patient recruitment to at-home sample collection to telemedicine visits. This could be a game-changer in improving patient diversity in trials and enabling studies focused on rare diseases or targeted therapies.

According to Science 37’s latest financial update, the company expects approximately $58-59 million in revenue for 2023 and over $50 million in cash reserves as of December 31, 2023. The company projected 2023 revenue of $50-60 million.

Science 37’s board of directors unanimously approved the acquisition deal with eMed. Major Science 37 shareholders, including Redmile Group, LLC, have also agreed to tender their shares in support of the acquisition.

The deal is expected to close in Q1 2024, pending tender of a majority of outstanding Science 37 shares and satisfaction of other customary closing conditions. Once completed, Science 37 will become a privately held subsidiary of eMed.

This Science 37 acquisition comes on the heels of eMed’s parent company, Evernow Inc., raising $100 million in Series B funding last March. The current deal highlights continued investor appetite for telehealth and digital health companies that are expanding access to care.

In fact, Noble Capital Markets will be hosting a Virtual Healthcare Conference from on April 17-18, 2024, featuring presentations from emerging growth companies in the healthcare sector. The conference will provide a platform for companies to showcase their innovations in digital health, telemedicine, medical devices and more.

The Science 37 and eMed deal also demonstrates the growing intersection between telehealth and clinical research. Other companies like Medable and Excelya are exploring how hybrid and decentralized trials can boost patient recruitment and retention. By meeting patients where they are, virtual trials enable more representative, diverse study populations.

While some industry experts say a hybrid approach will become the standard, decentralized trials are still a relatively new model. This acquisition provides eMed with a first-mover advantage, but expect other digital health companies to underscore their clinical trial offerings moving forward. In the meantime, all eyes will be on eMed and Science 37 as they pioneer the next generation of virtual clinical research.